Duopharma Biotech Berhad Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Duopharma Biotech Berhad Stock Forecast and Price Target
Duopharma Biotech Berhad has an average price target of RM1.49 recently offered by two notable experts for 2024, which would represent a potential upside of approximately 25.21% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of RM1.52 and a low estimate of RM1.41. If you are looking to invest in the stock, it's important to research and compare different companies.
25.21% Upside
Duopharma Biotech Berhad Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Duopharma Biotech Berhad's Price has decreased by 100.00%, going from RM1.06 to RM0.00. For next year, analysts predict Fair Value of RM0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Duopharma Biotech Berhad's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AHEALTH Stock Forecast | Apex Healthcare Berhad | Hold |
18
|
RM3.10 | Buy/Sell | RM2.55 | -14.84% |
| KOTRA Stock Forecast | Kotra Industries Berhad | Outperform |
16
|
RM4.71 | Buy/Sell | RM5.79 | 14.65% |
| YSPSAH Stock Forecast | Y.S.P. Southeast Asia Holding ... | - |
6
|
RM2.47 | Buy/Sell | RM3.00 | -100.00% |
| NOVA Stock Forecast | Nova Wellness Group Berhad | Outperform |
16
|
RM0.53 | Buy/Sell | RM0.72 | 28.30% |
| RHONEMA Stock Forecast | Rhone Ma Holdings Berhad | Hold |
0
|
RM0.67 | Buy/Sell | RM0.68 | 1.49% |
Duopharma Biotech Berhad Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Duopharma Biotech Berhad's Revenue has grown by 22.25%, rising from RM569.90M to RM696.72M. 0 analysts predict Duopharma Biotech Berhad's Revenue will decrease by 9.12% in the next year, reaching RM633.18M. By 2030, professionals predict that Duopharma Biotech Berhad's Revenue will decrease by 8.66%, to RM636.36M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUNZEN Stock Forecast | Sunzen Biotech Berhad | - |
0
|
RM0.28 | Buy/Sell | RM0.00 | -100.00% |
| BIOHLDG Stock Forecast | Bioalpha Holdings Berhad | - |
0
|
RM0.09 | Buy/Sell | RM0.24 | -100.00% |
| PLABS Stock Forecast | PeterLabs Holdings Berhad | - |
12
|
RM0.20 | Buy/Sell | RM0.00 | -100.00% |
.jpg)
Duopharma Biotech Berhad Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Duopharma Biotech Berhad's Dividend per Share has decreased from RM0.05 to RM0.02 – a 60.00% drop. For next year, analysts predict Dividend per Share of RM0.03, which would mean an increase of 50.00%. Over the next eight years, experts predict that Duopharma Biotech Berhad's Dividend per Share will grow at a rate of 61.20%.
Duopharma Biotech Berhad EBITDA Forecast for 2023 - 2025 - 2030
Duopharma Biotech Berhad's EBITDA has grown In the last two years, rising from RM105.11M to RM122.86M – a growth of 16.89%. The next year, 0 experts forecast that Duopharma Biotech Berhad's EBITDA will decrease by 7.15%, reaching RM114.08M. In 2030, professionals predict that Duopharma Biotech Berhad's EBITDA will decrease by 6.87%, reaching RM114.42M.
Duopharma Biotech Berhad EBIT Forecast for 2023 - 2025 - 2030
Duopharma Biotech Berhad's EBIT has seen impressive growth In the last two years, rising from RM81.04M to RM92.91M – a growth of 14.65%. According to the 0 analysts polled, in the next year, Duopharma Biotech Berhad's EBIT will fall by 5.88%, reaching RM87.45M. By 2030, professionals believe that Duopharma Biotech Berhad's EBIT will have decreased by 5.67%, falling to RM87.64M.
Duopharma Biotech Berhad EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Duopharma Biotech Berhad's EPS has decreased by 100.00%, going from RM0.06 to RM0.00. For next year, analysts predict EPS of RM0.00, which would mean an increase of 100.00%. Over the next six years, experts predict that Duopharma Biotech Berhad's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)